BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 7, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 2007

View Archived Issues

Diabetes snapshots: new data on GLP-1 receptor agonists

Read More

Strontium malonate offers better bioavailability than strontium ranelate

Read More

Oral fluoroquinolone prodrug safe in monkey studies

Read More

Studies reveal properties of potential COPD treatment aclidinium bromide

Read More

R-667 alters blood glucose in patients with COPD-emphysema

Read More

FDA accepts Nitec's IND for Lodotra

Read More

immatics begins phase II study of IMA-901 for renal cell cancer

Read More

Alkermes and Indevus state positive results from phase IIa study of ALKS-27 in COPD

Read More

Kyorin's novel fluoroquinolone more effective than moxifloxacin in vitro and in vivo

Read More

Kyowa Hakko launches Topina in Japan

Read More

VaxInnate commences clinical trials with M2e universal influenza vaccine

Read More

Santhera to file NDS for SNT-MC17 for Friedreich's ataxia in Canada

Read More

Recordati completes double-blind portion of phase III Urief trial for BPH

Read More

INCB-9471 safe and well tolerated in clinical studies

Read More

Wilex successfully completes WX-671 phase Ib trial in head and neck cancer

Read More

Alemtuzumab enters phase III program for MS indication

Read More

InterMune's ITMN-191 enters phase Ib trial in chronic HCV patients

Read More

Nastech initiates phase II clinical trial for insulin nasal spray

Read More

Protherics licenses CoVaccine HT adjuvant to Nobilon

Read More

NexMed files NDA for topically applied alprostadil cream

Read More

Velcura reports pre-IND meeting with FDA for VEL-0230 for bone disease

Read More

Knopp begins phase I trial of small-molecule KNS-760704 for ALS

Read More

Update on Pipex's development of oral Coprexa for Wilson's disease

Read More

SyntheMed's Repel-CV adhesion barrier recommended approval by FDA panel

Read More

Onyvax begins phase IIb trial of cell vaccine Onyvax-P for prostate cancer

Read More

FDA issues nonapprovable letter for Novartis' Prexige

Read More

MGI Pharma submits NDA to FDA for Aquavan

Read More

NeurogesX submits MAA to EMEA for NGX-4010 for peripheral neuropathic pain

Read More

Recent patents describe new treatment options for endocrine-related disorders

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • Liver disease

    FB-7033 demonstrates efficacy in MASH management

    BioWorld Science
    17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • Illustration of antibody carrying radioactive isotope

    Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

    BioWorld Science
    At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing